Finally, we demonstrate a correlation between NFκB activation, IL-6 expression and cervical disease progression, suggesting that targeting the IL-6 pathway to prevent STAT3 activation may have therapeutic benefits in cervical cancer. Here, NFKB1 is linked to cervical carcinoma.